Rights and permissions
About this article
Cite this article
Linezolid potentially less costly than teicoplanin in Gram-positive infections. Pharmacoecon. Outcomes News 425, 6 (2003). https://doi.org/10.1007/BF03276640
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03276640